Shanghai Rightongene Biotechnology Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 119.63 million compared to CNY 171.99 million a year ago. Revenue was CNY 127.57 million compared to CNY 172.71 million a year ago.

Net income was CNY 16.24 million compared to CNY 21.28 million a year ago. Basic earnings per share from continuing operations was CNY 0.29 compared to CNY 0.38 a year ago. Diluted earnings per share from continuing operations was CNY 0.29 compared to CNY 0.38 a year ago.